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Purpose: Interleukin 1β (IL-1β) is considered one of the key players in
osteoarthritis (OA) pathogenesis. It increases the transcription of several
mediators and enzymes, amongst which the inducible cycloxygenase iso-
form (COX2). Bradykinin (BK, H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH)
is a proinﬂammatory and algogenic peptide which is enzymatically gener-
ated from kininogen precursors circulating in plasma and interstitial ﬂuids.
BK, also detected into the synovial ﬂuid, activates B2 receptors present
on the membrane of ﬁbroblast-like synoviocytes to release prostaglandins,
cytokines and chemokines. Aim of this study was to investigate the inter-
action of BK with IL-1β, at concentrations resembling those measured in
the OA synovial ﬂuid, and to evaluate the effect of BK B2 receptor blockade,
by using the highly selective and potent B2 receptor antagonist MEN16132
(m.w. 873.16).
Methods: Human synoviocytes (ECACC, 408-05a) were cultured in synovio-
cyte growth medium (ECACC, 06091516) supplemented with Gln 2mM,
penicillin (50 μg/ml), streptomycin (50 μg/ml), amphotericin B (0.75
μg/ml). Experiments were performed with cells at conﬂuence plated onto
12-well plates. Cells were incubated at the indicated compound concentra-
tion in F12 medium supplemented with foetal bovine serum (1%), Gln (2
mM), and captopril (1 μM). At the end of the experiments, surnatants were
stored at -80°C and used for PGE2 content detection (Cayman, 514010),
whereas cells were collected for RNA extraction and following qPCR COX2
gene expression. Data are expressed as -fold increase versus untreated
cells (basal) and represent the mean ± s.e.m. of 3-4 experiments, each in
duplicate.
Results: A prolonged incubation (24h) of synoviocytes with BK (1 μM)
induced a signiﬁcant production of PGE2 (3.2±0.8 -fold of basal) and COX2
gene expression (1.9±0.3 -fold of basal). However, PGE2 production and
COX2 gene expression were reduced by the pretreatment (30 min) with the
B2 receptor antagonist MEN16132 (1 μM) (PGE2: 1.6±0.3; COX2: 0.7±0.1
-fold of basal), which per se did not affect the basal release of PGE2 (1.1±0.2
-fold of basal) or the COX2 gene expression (0.9±0.2 -fold of basal). In
contrast, the effect of IL-1β (15 pg/ml) was signiﬁcantly more pronounced,
since it augmented the PGE2 release by 44.7±13.3 -fold and the COX2
gene expression by 11.2±2.1 -fold in respect to basal values obtained in
control cells. The combined treatment of cells with BK and IL-1β induced
an even increase, both in terms of released PGE2 (148.0±35.4 -fold of
basal) and COX2 gene expression (28.2±4.9 -fold of basal), which indicated
a synergistic rather than an additive effect. These potentiating effects of
BK on both the PGE2 production and increased COX2 gene expression
produced by IL-1β were B2 receptor mediated such as the pretreatment
with the the B2 receptor antagonist could prevent it (PGE2: 54.6±7.3;
COX2: 14.0±2.5 -fold of basal).
Conclusions: These results indicate that BK has potentiating effect on the
COX2 gene expression and consequent prostanoid production induced by
IL-1β, and suggest that B2 receptor blockade by MEN16132 may represent
a potential symptomatic therapy for OA.
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Purpose: Alterations in osteoblast metabolism may play a role in os-
teoarthritis (OA). We have shown previously that heme oxygenese-1
(HO-1) exerts protective effects in cartilage by decreasing the production
of inﬂammatory and degenerative mediators. In this study, we have inves-
tigated the role of HO-1 in the regulation of the inﬂammatory response in
OA osteoblasts.
Methods: Osteoblasts were obtained from 7 OA patients undergoing total
knee joint replacement. Bone tissue from the trabecular area of the tibial
plateau was minced into small portions and digested with collagenase IA
for 2 h under agitation. Samples were then seeded in 100 mm petri dishes
in osteogenic medium. Bone pieces were removed and osteoblasts were
allowed to grow until third passage. Cells were treated with the HO-1
inducer cobalt protoporphyrin IX (CoPP, 10 μM) in the presence or absence
of interleukin-1β (IL-1β, 10 ng/ml) for 3 h (mRNA determination) or 24 h
(other determinations). Matrix mineralization was determined by Alizarin
red incorporation. Gene expression was analyzed by quantitative PCR and
protein expression by Western Blot and ELISA. Matrix metalloproteinase
(MMP) activity was determined by ﬂuorometric procedures and PGE2 by
RIA.
Results: IL-1β inhibited protein expression of HO-1 in osteoblasts with
respect to basal conditions. This pro-inﬂammatory cytokine signiﬁcantly in-
creased MMP activity and PGE2 production. These effects were signiﬁcantly
reverted by CoPP treatment. PCR analysis showed the down-regulation of
HO-1 mRNA induced by IL-1β, and the up-regulation of COX-2, mPGES-1,
MMP-1, MMP-2, MMP-3, IL-6, HMGB-1 and RAGE. CoPP was also able to
signiﬁcantly revert these effects of IL-1β. Inhibition of PGE2 production
by CoPP would be dependent on the decreased expression of COX-2 and
mPGES-1, a key mediator of bone destruction associated with inﬂammation.
Conclusions: In this work we have shown that HO-1 decreases the produc-
tion of relevant inﬂammatory and catabolic mediators that participate in OA
pathophysiology. Our data suggest that HO-1 could be a pharmacological
target to control the activity of osteoblasts.
457
EFFECT OF IL-1β ON THE PROTEOME OF CHONDROCYTES DERIVED FROM
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Purpose: Inﬂammation plays a pivotal role in cartilage tissue destruction in
osteoarthritis. IL-1β, a key mediator, affects the balance of biosynthesis and
degradation of extracellular matrix (ECM) constituents by chondrocytes.
Indeed, exuberant synthesis of matrix metalloproteinases and reduced
expression of collagen II and aggrecan are well-known cytokine-mediated
hallmarks of osteoarthritis. In addition, IL-1β induces the production of
the pain mediator prostaglandin E2 via cyclooxygenase which decisively
contributes to joint dysfunction. Today’s treatment options are restricted
to symptome-modifying drugs. However, analgesics or anti-inﬂammatory
drugs partially show just limited eﬃcacy with respect to pain relief or cause
undesirable side effects. Hence, the identiﬁcation of disease-modifying and
eﬃcient symptome-modifying drugs is a main challenge in osteoarthritis
research.
Methods: Pharmacoproteomics is a promising approach for drug screening.
In order to establish a reference system for monitoring substance effects,
we performed proteome proﬁling of human osteoarthritic chondrocytes. Al-
terations of the secretion performance and the metabolism of chondrocytes
due to IL-1 β treatment were assessed by 2D-PAGE and shotgun proteomics
combined with the mass spectrometrical identiﬁcation of proteins.
Results: A special focus was laid on the determination of interindividual
differences existing per se as well as those arising due to stimulation
by IL-1β. The proteomes were functionally characterized and biomark-
ers/functions reﬂecting the cytokine effect were gathered. We identiﬁed
well-known markers for cartilage degradation such as MMP-1 and IL-6, IL-8
among many others in the context of a global cytokine-induces alteration
of gene expression. The resulting database was used to assess the effect of
different derivatives of hyaluronic acid in order to evaluate the applicability
of this approach.
Conclusions: Our approach enabled insights into molecular alterations
due to cytokine and substance effects at a comprehensive systemic level.
Furthermore, it proved to be well-suited to identify "real" substance effects
against the background of the patient- and disease-derived heterogeneity
of samples.
